Literature DB >> 2281807

Therapeutic effects of fengabine, a new GABAergic agent, in depressed outpatients: a double-blind study versus clomipramine.

N P Nielsen1, B Cesana, S Zizolfi, V Ascalone, P Priore, P L Morselli.   

Abstract

The results of a double-blind clinical trial of fengabine vs clomipramine in depressed outpatients are reported. Fengabine, a new GABAergic agent, seems to be as effective as the reference drug, with a faster onset of action and a more marked effect on cognitive disturbances and retardation. The new drug is free of any significant anticholinergic or cardiovascular effect, and it is not sedative.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2281807     DOI： 10.1111/j.1600-0447.1990.tb01402.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN： 0001-690X            Impact factor:   6.392


  4 in total

Review 1.  Neurochemical and metabolic aspects of antidepressants: an overview.

Authors:  G B Baker; R T Coutts; A J Greenshaw
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

2.  Normal [3H]flunitrazepam binding to GABAA receptors in the locus coeruleus in major depression and suicide.

Authors:  He Zhu; Beata Karolewicz; Emily Nail; Craig A Stockmeier; Katalin Szebeni; Gregory A Ordway
Journal:  Brain Res       Date:  2006-11-21       Impact factor: 3.252

3.  A placebo controlled double-blind evaluation of the pharmacodynamics of fengabine vs amitriptyline following single and multiple doses in elderly volunteers.

Authors:  D B Fairweather; J S Kerr; S Hilton; I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

4.  Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression.

Authors:  Beata Karolewicz; Dorota Maciag; Gillian O'Dwyer; Craig A Stockmeier; Anteneh M Feyissa; Grazyna Rajkowska
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-15       Impact factor: 5.176
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.